Table of Contents

2019-2024 Global Haemophilia Treatment Consumption Market Report

1 Scope of the Report

• 1.1 Market Introduction
• 1.2 Research Objectives
• 1.3 Years Considered
• 1.4 Market Research Methodology
• 1.5 Economic Indicators
• 1.6 Currency Considered

2 Executive Summary

• 2.1 World Market Overview
  • 2.1.1 Global Haemophilia Treatment Consumption 2014-2024
  • 2.1.2 Haemophilia Treatment Consumption CAGR by Region
• 2.2 Haemophilia Treatment Segment by Type
  • 2.2.1 Haemophilia A
  • 2.2.2 Haemophilia B
• 2.3 Haemophilia Treatment Consumption by Type
  • 2.3.1 Global Haemophilia Treatment Consumption Market Share by Type (2014-2019)
  • 2.3.2 Global Haemophilia Treatment Revenue and Market Share by Type (2014-2019)
  • 2.3.3 Global Haemophilia Treatment Sale Price by Type (2014-2019)
• 2.4 Haemophilia Treatment Segment by Application
  • 2.4.1 Hospital
  • 2.4.2 Pharmaceutical Companies
  • 2.4.3 Other
• 2.5 Haemophilia Treatment Consumption by Application
  • 2.5.1 Global Haemophilia Treatment Consumption Market Share by Application (2014-2019)
  • 2.5.2 Global Haemophilia Treatment Value and Market Share by Application (2014-2019)
  • 2.5.3 Global Haemophilia Treatment Sale Price by Application (2014-2019)

3 Global Haemophilia Treatment by Manufacturers

• 3.1 Global Haemophilia Treatment Sales Market Share by Manufacturers
  • 3.1.1 Global Haemophilia Treatment Sales by Manufacturers (2017-2019)
  • 3.1.2 Global Haemophilia Treatment Sales Market Share by Manufacturers (2017-2019)
• 3.2 Global Haemophilia Treatment Revenue Market Share by Manufacturers
  • 3.2.1 Global Haemophilia Treatment Revenue by Manufacturers (2017-2019)
  • 3.2.2 Global Haemophilia Treatment Revenue Market Share by Manufacturers (2017-2019)
• 3.3 Global Haemophilia Treatment Sale Price by Manufacturers
• 3.4 Global Haemophilia Treatment Manufacturing Base Distribution, Sales Area, Product Types by Manufacturers
  • 3.4.1 Global Haemophilia Treatment Manufacturing Base Distribution and Sales Area by Manufacturers
  • 3.4.2 Players Haemophilia Treatment Products Offered
• 3.5 Market Concentration Rate Analysis
  • 3.5.1 Competition Landscape Analysis
  • 3.5.2 Concentration Ratio (CR3, CR5 and CR10) (2017-2019)
• 3.6 New Products and Potential Entrants
• 3.7 Mergers & Acquisitions, Expansion

4 Haemophilia Treatment by Regions

• 4.1 Haemophilia Treatment by Regions
  • 4.1.1 Global Haemophilia Treatment Consumption by Regions
  • 4.1.2 Global Haemophilia Treatment Value by Regions
• 4.2 Americas Haemophilia Treatment Consumption Growth
• 4.3 APAC Haemophilia Treatment Consumption Growth
• 4.4 Europe Haemophilia Treatment Consumption Growth
• 4.5 Middle East & Africa Haemophilia Treatment Consumption Growth

5 Americas

• 5.1 Americas Haemophilia Treatment Consumption by Countries
  • 5.1.1 Americas Haemophilia Treatment Consumption by Countries (2014-2019)
  • 5.1.2 Americas Haemophilia Treatment Value by Countries (2014-2019)
• 5.2 Americas Haemophilia Treatment Consumption by Type
• 5.3 Americas Haemophilia Treatment Consumption by Application
• 5.4 United States
• 5.5 Canada
• 5.6 Mexico
• 5.7 Key Economic Indicators of Few Americas Countries

6 APAC

• 6.1 APAC Haemophilia Treatment Consumption by Countries
  • 6.1.1 APAC Haemophilia Treatment Consumption by Countries (2014-2019)
  • 6.1.2 APAC Haemophilia Treatment Value by Countries (2014-2019)
• 6.2 APAC Haemophilia Treatment Consumption by Type
• 6.3 APAC Haemophilia Treatment Consumption by Application
• 6.4 China
• 6.5 Japan
• 6.6 Korea
• 6.7 Southeast Asia
• 6.8 India
• 6.9 Australia
• 6.10 Key Economic Indicators of Few APAC Countries

7 Europe

• 7.1 Europe Haemophilia Treatment by Countries
  • 7.1.1 Europe Haemophilia Treatment Consumption by Countries (2014-2019)
  • 7.1.2 Europe Haemophilia Treatment Value by Countries (2014-2019)
• 7.2 Europe Haemophilia Treatment Consumption by Type
• 7.3 Europe Haemophilia Treatment Consumption by Application
• 7.4 Germany
• 7.5 France
• 7.6 UK
• 7.7 Italy
• 7.8 Russia
• 7.9 Spain
• 7.10 Key Economic Indicators of Few Europe Countries

8 Middle East & Africa

• 8.1 Middle East & Africa Haemophilia Treatment by Countries
  • 8.1.1 Middle East & Africa Haemophilia Treatment Consumption by Countries (2014-2019)
  • 8.1.2 Middle East & Africa Haemophilia Treatment Value by Countries (2014-2019)
• 8.2 Middle East & Africa Haemophilia Treatment Consumption by Type
• 8.3 Middle East & Africa Haemophilia Treatment Consumption by Application
• 8.4 Egypt
• 8.5 South Africa
• 8.6 Israel
• 8.7 Turkey
• 8.8 GCC Countries

9 Market Drivers, Challenges and Trends

• 9.1 Market Drivers and Impact
  • 9.1.1 Growing Demand from Key Regions
  • 9.1.2 Growing Demand from Key Applications and Potential Industries
• 9.2 Market Challenges and Impact
• 9.3 Market Trends

10 Marketing, Distributors and Customer

• 10.1 Sales Channel
  • 10.1.1 Direct Channels
  • 10.1.2 Indirect Channels
• 10.2 Haemophilia Treatment Distributors
• 10.3 Haemophilia Treatment Customer

11 Global Haemophilia Treatment Market Forecast

• 11.1 Global Haemophilia Treatment Consumption Forecast (2019-2024)
• 11.2 Global Haemophilia Treatment Forecast by Regions
  • 11.2.1 Global Haemophilia Treatment Forecast by Regions (2019-2024)
  • 11.2.2 Global Haemophilia Treatment Value Forecast by Regions (2019-2024)
  • 11.2.3 Americas Consumption Forecast
  • 11.2.4 APAC Consumption Forecast
  • 11.2.5 Europe Consumption Forecast
  • 11.2.6 Middle East & Africa Consumption Forecast
• 11.3 Americas Forecast by Countries
  • 11.3.1 United States Market Forecast
  • 11.3.2 Canada Market Forecast
  • 11.3.3 Mexico Market Forecast
  • 11.3.4 Brazil Market Forecast
• 11.4 APAC Forecast by Countries
  • 11.4.1 China Market Forecast
  • 11.4.2 Japan Market Forecast
  • 11.4.3 Korea Market Forecast
  • 11.4.4 Southeast Asia Market Forecast
  • 11.4.5 India Market Forecast
  • 11.4.6 Australia Market Forecast
• 11.5 Europe Forecast by Countries
  • 11.5.1 Germany Market Forecast
  • 11.5.2 France Market Forecast
  • 11.5.3 UK Market Forecast
  • 11.5.4 Italy Market Forecast
  • 11.5.5 Russia Market Forecast
  • 11.5.6 Spain Market Forecast
• 11.6 Middle East & Africa Forecast by Countries
  • 11.6.1 Egypt Market Forecast
  • 11.6.2 South Africa Market Forecast
  • 11.6.3 Israel Market Forecast
  • 11.6.4 Turkey Market Forecast
  • 11.6.5 GCC Countries Market Forecast
• 11.7 Global Haemophilia Treatment Forecast by Type
• 11.8 Global Haemophilia Treatment Forecast by Application

12 Key Players Analysis

• 12.1 Bayer
  • 12.1.1 Company Details
  • 12.1.2 Haemophilia Treatment Product Offered
  • 12.1.3 Bayer Haemophilia Treatment Sales, Revenue, Price and Gross Margin (2017-2019)
  • 12.1.4 Main Business Overview
  • 12.1.5 Bayer News
• 12.2 Novo Nordisk
  • 12.2.1 Company Details
  • 12.2.2 Haemophilia Treatment Product Offered
  • 12.2.3 Novo Nordisk Haemophilia Treatment Sales, Revenue, Price and Gross Margin (2017-2019)
  • 12.2.4 Main Business Overview
  • 12.2.5 Novo Nordisk News
• 12.3 Pfizer
  • 12.3.1 Company Details
  • 12.3.2 Haemophilia Treatment Product Offered
  • 12.3.3 Pfizer Haemophilia Treatment Sales, Revenue, Price and Gross Margin (2017-2019)
  • 12.3.4 Main Business Overview
  • 12.3.5 Pfizer News
• 12.4 Roche
  • 12.4.1 Company Details
  • 12.4.2 Haemophilia Treatment Product Offered
  • 12.4.3 Roche Haemophilia Treatment Sales, Revenue, Price and Gross Margin (2017-2019)
  • 12.4.4 Main Business Overview
  • 12.4.5 Roche News
• 12.5 Aptevo Therapeutics
  • 12.5.1 Company Details
  • 12.5.2 Haemophilia Treatment Product Offered
  • 12.5.3 Aptevo Therapeutics Haemophilia Treatment Sales, Revenue, Price and Gross Margin (2017-2019)
  • 12.5.4 Main Business Overview
  • 12.5.5 Aptevo Therapeutics News
• 12.6 Catalyst BioSciences
  • 12.6.1 Company Details
  • 12.6.2 Haemophilia Treatment Product Offered
  • 12.6.3 Catalyst BioSciences Haemophilia Treatment Sales, Revenue, Price and Gross Margin (2017-2019)
  • 12.6.4 Main Business Overview
  • 12.6.5 Catalyst BioSciences News
• 12.7 Dimension Therapeutics
  • 12.7.1 Company Details
  • 12.7.2 Haemophilia Treatment Product Offered
  • 12.7.3 Dimension Therapeutics Haemophilia Treatment Sales, Revenue, Price and Gross Margin (2017-2019)
  • 12.7.4 Main Business Overview
  • 12.7.5 Dimension Therapeutics News
• 12.8 Shire
  • 12.8.1 Company Details
  • 12.8.2 Haemophilia Treatment Product Offered
  • 12.8.3 Shire Haemophilia Treatment Sales, Revenue, Price and Gross Margin (2017-2019)
  • 12.8.4 Main Business Overview
  • 12.8.5 Shire News
• 12.9 CSL Behring
  • 12.9.1 Company Details
  • 12.9.2 Haemophilia Treatment Product Offered
  • 12.9.3 CSL Behring Haemophilia Treatment Sales, Revenue, Price and Gross Margin (2017-2019)
  • 12.9.4 Main Business Overview
  • 12.9.5 CSL Behring News
• 12.10 Alnylam Pharmaceuticals
  • 12.10.1 Company Details
  • 12.10.2 Haemophilia Treatment Product Offered
  • 12.10.3 Alnylam Pharmaceuticals Haemophilia Treatment Sales, Revenue, Price and Gross Margin (2017-2019)
  • 12.10.4 Main Business Overview
  • 12.10.5 Alnylam Pharmaceuticals News

13 Research Findings and Conclusion

Haemophilia is a mostly inherited genetic disorder that impairs the body's ability to make blood clots, a process needed to stop bleeding.

According to this study, over the next five years the Haemophilia Treatment market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2024, from US$ xx million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Haemophilia Treatment business, shared in Chapter 3.

This report presents a comprehensive overview, market shares, and growth opportunities of Haemophilia Treatment market by product type, application, key manufacturers and key regions and countries.

This study considers the Haemophilia Treatment value and volume generated from the sales of the following segments:

Segmentation by product type: breakdown data from 2014 to 2019, in Section 2.3; and forecast to 2024 in section 11.7.
Haemophilia A
Haemophilia B
Segmentation by application: breakdown data from 2014 to 2019, in Section 2.4; and forecast to 2024 in section 11.8.
Hospital
Pharmaceutical Companies
Other

This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Spain
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in in Chapter 3.
Bayer
Novo Nordisk
Pfizer
Roche
Aptevo Therapeutics
Catalyst BioSciences
Dimension Therapeutics
Shire
CSL Behring
Alnylam Pharmaceuticals

In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.

Research objectives
To study and analyze the global Haemophilia Treatment consumption (value & volume) by key regions/countries, product type and application, history data from 2014 to 2018, and forecast to 2024.
To understand the structure of Haemophilia Treatment market by identifying its various subsegments.
Focuses on the key global Haemophilia Treatment manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Haemophilia Treatment with respect to individual growth trends, future prospects, and their contribution to the total market.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To project the consumption of Haemophilia Treatment submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.